Additionally, a higher percentage of SIRPGlow CD8+ peripheral T cells has been reported in patients with T1D and relapsing-remitting multiple sclerosis (RRMS), independent of genotype (19), implying SIRPG may inhibit adaptive immunity and offer protection in autoimmune diseases. Here, CD8A is linked to relapsing-remitting multiple sclerosis.